Coherus Oncology, Inc. (CHRS) Cash Flow Statement
Coherus Oncology, Inc. (CHRS) generated -$186.0M of operating cash flow over the twelve months to 2026-06-30, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
CHRSCoherus Oncology, Inc.Follow CHRS — free
—
Price chart with a free account
- Market cap
- 156.0M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 9 Nov, in 16 days
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -23.9 | -108.0 | -252.5 | -200.3 | 28.4 | 154.1 | -37.4 | -241.1 | -174.9 | -20.4 | -138.5 | -186.0 | |
| Capital expenditure | 2.8 | 6.2 | 6.5 | 4.6 | 1.8 | 7.2 | 1.3 | 2.0 | 0.3 | — | — | — | |
| Free cash flow | -26.8 | -114.2 | -259.1 | -204.9 | 26.5 | 146.9 | -38.7 | -243.2 | -175.2 | — | — | — | |
| Share repurchases | 0.0 | — | — | — | — | — | — | — | — | — | — | — | |
| Stock-based compensation | 11.1 | 16.7 | 27.4 | 33.4 | 33.6 | 38.2 | 51.4 | 50.7 | 43.1 | 27.8 | 17.0 | — |
USD millions · SEC XBRL
Coherus Oncology, Inc. — questions
- What is Coherus Oncology, Inc.'s operating cash flow?
- -$186.0M over the twelve months to 2026-06-30.
Every figure on this page comes from Coherus Oncology, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.